Moderna (NASDAQ:MRNA) Receives “In-Line” Rating from Evercore ISI

Evercore ISI reissued their in-line rating on shares of Moderna (NASDAQ:MRNA) in a research note released on Thursday, Benzinga reports. They currently have a $120.00 target price on the stock.

MRNA has been the topic of a number of other reports. UBS Group boosted their target price on shares of Moderna from $143.00 to $151.00 and gave the stock a buy rating in a research report on Tuesday, May 7th. Oppenheimer boosted their target price on shares of Moderna from $163.00 to $179.00 and gave the stock an outperform rating in a research report on Wednesday, June 12th. Canaccord Genuity Group boosted their target price on shares of Moderna from $91.00 to $106.00 and gave the stock a hold rating in a research report on Friday, May 3rd. Jefferies Financial Group reissued a buy rating and set a $125.00 target price on shares of Moderna in a research report on Tuesday, April 9th. Finally, William Blair restated a market perform rating on shares of Moderna in a research note on Monday, April 1st. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of Hold and an average price target of $134.02.

Moderna Stock Down 1.0 %

Shares of MRNA stock opened at $121.18 on Thursday. The firm’s 50 day moving average price is $133.78 and its two-hundred day moving average price is $111.47. Moderna has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. During the same period in the previous year, the company posted $0.19 earnings per share. The business’s revenue for the quarter was down 91.0% compared to the same quarter last year. Research analysts predict that Moderna will post -7.46 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the completion of the sale, the president now owns 1,457,089 shares in the company, valued at $201,311,416.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, President Stephen Hoge sold 15,000 shares of the stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $138.16, for a total value of $2,072,400.00. Following the sale, the president now owns 1,457,089 shares of the company’s stock, valued at approximately $201,311,416.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 705 shares of the stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the completion of the sale, the chief financial officer now directly owns 5,048 shares in the company, valued at approximately $514,542.64. The disclosure for this sale can be found here. Insiders sold a total of 396,255 shares of company stock worth $54,210,631 over the last 90 days. Insiders own 15.70% of the company’s stock.

Institutional Trading of Moderna

Large investors have recently modified their holdings of the company. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Moderna in the 4th quarter worth about $27,000. Arlington Trust Co LLC increased its holdings in shares of Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after acquiring an additional 290 shares during the period. Cedar Wealth Management LLC grew its position in Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares in the last quarter. Westside Investment Management Inc. bought a new position in Moderna in the 1st quarter valued at about $32,000. Finally, Rise Advisors LLC grew its position in Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after buying an additional 286 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.